VEGF₁₆₅, Human, Recombinant, S. frugiperda

Recombinant, human VEGF₁₆₅ (165 amino acid splice variant of VEGF) expressed in S. frugiperda insect cells. A heparin-binding glycoprotein with potent angiogenic, endothelial cell-specific mitogenic and vascular permeability-enhancing activities. Increases endothelial cell proliferation after vascular injury. Supplied as a glycosylated, disulfied-linked homodimer.

Recombinant, human VEGF₁₆₅ (165 amino acid splice variant of VEGF) expressed in S. frugiperda insect cells. A heparin-binding glycoprotein with potent angiogenic, endothelial cell-specific mitogenic, and vascular permeability-enhancing activities. Increases endothelial cell proliferation after vascular injury. Supplied as a glycosylated, disulfide-linked homodimer.

ED₅₀ = 2.0-6.0 ng/ml as measured by its ability to stimulate ³H-thymidine incorporation into human umbilical vein endothelial cells

Toxicity: Standard Handling (A)

Lyophilized from sterile-filtered 30% acetonitrile, 0.1% TFA, 50 µg BSA/µg VEGF.

Following reconstitution, aliquot and freeze (-70°C). Avoid freeze/thaw cycles of solutions. Stock solutions are stable for up to 3 months at -70°C.

Reconstitute to a final concentration of ≥1 µg/ml with sterile PBS containing ≥0.1% HSA or BSA.

Liu, X., et al. 2001. J. Urology166, 354.
Burke, P.A., et al. 1995. Biochem. Biophys. Res. Commun. 207, 348.
Neufeld, G., et al. 1994. Prog. Growth Factor Res.5, 89.
Leung, D.W., et al. 1989. Science 246, 1306.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany